Drug reviews

2025 Oregon PDAB drug review resources

This table provides links to the 2025 Oregon PDAB drug review documents, videos, minutes

Drug review group	Review documents	Meeting video	Meeting minutes
Vraylar, Entresto, Ajovy, Emgality, Nurtec, Ubrelvy	July 16, 2025	July 16, 2025	July 16, 2025
Trelegy, Eliquis, Xarelto, Cosentyx, Creon	Aug. 20, 2025	Aug. 20, 2025	Aug. 20, 2025
Jardiance, Mounjaro, Ozempic, Rybelsus, Trulicity	Sept. 17, 2025	Sept. 17, 2025	Sept. 17, 2025
Insulin products: Basaglar KwikPen, Insulin Glargine-yfgn, Lantus, Lantus SoloStar, Semglee, Toujeo Max SoloStar, Toujeo SoloStar	Oct. 15, 2025	Oct. 15, 2025	Oct. 15, 2025

About Oregon PDAB drug reviews: The Prescription Drug Affordability Board conducts annual drug reviews for identified drugs and insulin products as directed by ORS 646A.694 using criteria established in Oregon law. In the drug reviews, the board narrows a list of prescription drugs to a subset list, reviews each drug and applies criteria to determine whether the drugs may cause affordability challenges for Oregonians and health care systems in the state. The board submits a list of up to nine prescription drugs and at least one insulin product to the Oregon Legislature. Data for the reviews comes from the Drug Price Transparency (DPT) program pursuant to ORS 646A.694, the Oregon Health Authority All Claims All Payers (APAC) data base, and information submitted by insurance carriers through a data call by Department of Consumer Business Services.The board adopted two rules in 2023 to guide the board drug review process. OAR 925-200-0010 criteria for board selection of the subset list of drugs and OAR 925-200-0020 criteria for drug reviews.